Table 3.

Cumulative effect of 16 reported prostate cancer susceptibility SNPs on prostate cancer–specific survival

No. of risk alleles	Frequency in all patients	HR (95% CI)	P
≤8	0.03	1.43 (0.76–2.68)	0.26
9	0.05	1.78 (1.12–2.83)	0.01
10	0.09	1.25 (0.84–1.85)	0.27
11	0.13	1.53 (1.06–2.21)	0.02
12	0.14	1.23 (0.84–1.78)	0.29
13	0.16	1.00 (Referent)
14	0.14	1.30 (0.88–1.91)	0.19
15	0.11	0.88 (0.55–1.39)	0.58
16	0.07	1.50 (0.93–2.41)	0.09
17	0.04	0.73 (0.38–1.40)	0.34
≥18	0.04	1.60 (0.93–2.77)	0.09
P trend*	0.07

NOTE: Association between number of risk alleles carried and prostate cancer – specific survival was assessed in a Cox regression model using carriers of 13 risk variants as reference group. Covariates representing age, clinical stage, biopsy Gleason sum, diagnostic serum PSA level, and nodal and distal metastases were included.

Abbreviations: HR, hazard ratio; CI, confidence interval; PSA, prostate-specific antigen.

^*P value from a score test of a continuos variable representing number of risk alleles carried in a Cox regression analysis.